Last reviewed · How we verify
Formocresol
At a glance
| Generic name | Formocresol |
|---|---|
| Also known as | Buckley's solution, Medicaments for non-vital pulpotomy procedure, Buckley's Formocresol, medicament for Non-vital pulpotomy procedure |
| Sponsor | University of Sulaimani |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical and Radiographic Assessment of Neo Putty MTA Versus Formocresol Used in Vital Pulpotomy of Mandibular Primary Molars (NA)
- Use of Alkasite for Postpulpotomy Restoration (NA)
- Effectiveness of Premixed Bioactive Bioceramic MTA (Neo-Putty®) in Pulpotomies Primary Teeth
- New Vital Pulpotomy Medications in Primary Molars (NA)
- Clinical and Radiographic Evaluation of Chitosan Versus Formocresol After Vital Pulpotomy of Primary Molars (NA)
- Clinical and Radiographic Evaluation of Vital Pulpotomy Techniques in Primary Molars Using of Premixed Bioactive Bioceramic MTA (Neo-putty) as a Novel Pulpotomy Medication Versus Formocresol (NA)
- Lasers as an Alternative to Formocresol and Sodium Hypochlorite Medicaments in Pulpotomy Techniques (PHASE4)
- Clinical, Radiographic and Patient Acceptance Evaluation of LASER Compared to Formocresol Pulpotomies inPrimary Molars (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Formocresol CI brief — competitive landscape report
- Formocresol updates RSS · CI watch RSS
- University of Sulaimani portfolio CI